Lurbinectedin is a chemotherapy drug used to treat patients with small cell lung cancer (SCLC) that has progressed despite previous treatments. The drug works by blocking the activity of an enzyme called RNA polymerase II, which is involved in the transcription of DNA to RNA. While Lurbinectedin can be effective in treating SCLC, it can also cause a range of side effects [2].

Common side effects of Lurbinectedin include nausea, vomiting, fatigue, constipation, decreased appetite, and diarrhea. Patients may also experience hair loss, anemia, and low levels of white blood cells, which can increase the risk of infection. Additionally, Lurbinectedin can cause liver damage, which may result in elevated liver enzymes, abdominal pain, and jaundice [2][3].

Less common but more serious side effects of Lurbinectedin include an increased risk of blood clots, which can lead to stroke or heart attack, and lung damage, which can cause shortness of breath and coughing. Patients may also experience allergic reactions, including difficulty breathing, swelling of the face or throat, and hives [2][3].

Patients who experience any of these side effects while taking Lurbinectedin should contact their healthcare provider immediately. In some cases, dosage adjustments or discontinuation of the drug may be necessary to manage side effects [2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.mayoclinic.org/drugs-supplements/lurbinectedin-intravenous-route/side-effects/drg-20490804?p=1
[3] https://www.zepzelca.com/zepzelca-side-effects/